Bnar J. Hama Amin, Dana H. Mohammed Saeed, Hadi Mohammed Abdullah, Zana H. Mahmood, Karokh Fadhil Hamahussein, Hussein M. Hamasalih, Sabah Jalal Hasan, Sanaa O. Karim and 8 more
Introduction Clinical trials of COVID-19 vaccines were insufficient to detect uncommon adverse outcomes that are crucial for risk-benefit analyses and informing clinical practice post-vaccination. As a result, detection of infrequent adverse events has become a global research priority. The current study aims to…
Cardiopulmonary Complications Following COVID-19 Vaccinations: A Systematic Review
Bnar J. Hama Amin, Dana H. Mohammed Saeed, Hadi Mohammed Abdullah, Zana H. Mahmood, Karokh Fadhil Hamahussein, Hussein M. Hamasalih, Sabah Jalal Hasan, Sanaa O. Karim and 8 more
IntroductionClinical trials of COVID-19 vaccines were insufficient to detect uncommon adverse outcomes that are crucial for risk-benefit analyses and informing clinical practice post-vaccination. As a result, detection of infrequent adverse events has become a global research priority. The current study aims to estimate the rate of cardiopulmonary complications associated with COVID-19 vaccination.
MethodsTwo databases and one search engine were explored to identify English language-related studies published up to January 2023.
ResultsThe literature search turned up a total of 3974 relevant studies. Of them, 37 articles matched the inclusion criteria. Overall, seven studies from the United States. The mean age of patients was 25 years and about 77% of them were male. The most common reported consequence was inflammatory heart disease (myo-peri-cariditis), followed by pulmonary embolism (17%), and myocardial infarction (5%). The majority of complications were reported following mRNA COVID-19 vaccinations, particularly following the administration of the second dose. Pfizer has a slightly higher risk of cardiac complications following vaccination (4.1 per 100000 persons) than Moderna (3.7 per 100,000 persons).
ConclusionAlthough cardiopulmonary complications associated with COVID-19 vaccinations are uncommon, they can be life-threatening. Therefore, more large-scale observational studies and review articles of those studies are strongly recommended.
Fenk Mariwan Mohemed, Binaiy Nasih Fatih, Abdullah Abdulrahman Qadir, Shalaw H. Abdalla, Zana H. Mahmood
Introduction Cancer is the uncontrollable and abnormal division of cells in a specific part of the body, which can spread to adjacent areas. The number of scientific publications on cancer has increased significantly over the past few decades. The objective of the current study is to evaluate scientific publications…
Cancer Publications in One Year (2022): A Cross-Sectional Study
Fenk Mariwan Mohemed, Binaiy Nasih Fatih, Abdullah Abdulrahman Qadir, Shalaw H. Abdalla, Zana H. Mahmood
IntroductionCancer is the uncontrollable and abnormal division of cells in a specific part of the body, which can spread to adjacent areas. The number of scientific publications on cancer has increased significantly over the past few decades. The objective of the current study is to evaluate scientific publications on cancer in 2022.
MethodsA cross-sectional study was conducted on published papers on cancer in 2022. The data were collected online from the Google Scholar search engine and recorded in Microsoft Excel 2010. The extracted data were calculated and thoroughly re-evaluated, and they were presented as frequencies and percentages.
ResultsA total of 167,129 medical studies on cancer in various body organs were collected for the study, with 37,500 studies specifically focused on breast cancer. This represented the highest number of studies in 2022, while only 4 articles were specific to glottis cancer, marking the lowest number in that year.
ConclusionThe existence of a gap between the incidence rate of each cancer type and scientific literature may lead to a defect in our understanding of the nature of the diseases.
